List of Brilinta drug patents

Brilinta is owned by Astrazeneca.

Brilinta contains Ticagrelor.

Brilinta has a total of 6 drug patents out of which 0 drug patents have expired.

Brilinta was authorised for market use on 20 July, 2011.

Brilinta is available in tablet;oral dosage forms.

Brilinta can be used as treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily.

The generics of Brilinta are possible to be released after 27 July, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(2 years from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(7 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(7 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(13 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
M May 9, 2025
Pediatric Exclusivity (PED) Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily; Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; Treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in